Contact us


    Collection and Use of Personal Information. *


    Deep Bio’s AI Support for Prostate Cancer Diagnosis will be Deployed at Five Korean Hospitals

    October 10, 2022

    DeepDx®-Prostate Pro, designated as an Innovative Product by the Korea Public Procurement Service, is expected to improve pathology workflows in real clinical settings

    SEOUL, SOUTH KOREA (PRWEB) OCTOBER 10, 2022 – Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics software, announced that it will sign trial purchase agreements with five Korean hospitals for its AI-based prostate cancer diagnosis support software, DeepDx®-Prostate Pro, through the Public Procurement Marketplace program run by the Korean Public Procurement Service (PPS). The software was designated as an ‘Innovative Product’ in July 2022.

    To successfully complete the integration of DeepDx®-Prostate Pro into the pathology workflows by this November, the hospitals participating in the trial purchase – the SMG-SNU Boramae Medical Center, Chungnam National University Sejong Hospital, Korea Institute of Radiological & Medical Sciences, Jeju National University Hospital, and Gyeongsang National University Changwon Hospital – and Deep Bio are progressing through required procedures and making arrangements. The AI will be used for various purposes, including support for pathologists in tumor severity determination, confirmation of diagnoses, and research.

    DeepDx®-Prostate Pro is a deep learning-based medical software that assists the histopathological diagnosis of prostate cancer by analyzing the Whole Slide Image (WSI) of the prostate needle biopsies. It automatically classifies the severity of prostate cancer, which empowers pathologists to make diagnostic decisions with increased accuracy and speed.

    “We are greatly expecting to prove that our software can be seamlessly integrated into the current pathology workflows, bringing positive changes such as reducing pathologists’ work burden and improving efficiency in real clinical settings,” mentioned Sun-Woo Kim, CEO of Deep Bio. He also said, “through this trial purchase project, Deep Bio will lead the introduction of digital pathology in Korea as well as accelerate domestic market expansion.”

    Korea PPS’ ‘Innovative Product Designation Program’ is a government program that aims to foster the development of innovative technologies. To select Innovative Products, a committee made up of the Korea PPS and experts in each field, such as bio-health, future automobiles, and carbon neutrality, evaluates each registrant based on several criteria including public value and innovation.

    Focusing not only on AI diagnostics but also R&D, Deep Bio has been presenting its novel research results in prestigious science and technology journals including the Cancers Journal, npj Digital Medicine, as well as in various international conferences and events. The company also continues to build its global presence through overseas digital pathology platform providers in the US, Europe, and India, as well as conducting research cooperation with Stanford Medical School, Harvard Dana-Farber Cancer Institute, and other top research institutions in the US.

    About Deep Bio

    Deep Bio Inc. is an AI healthcare company with in-house expertise in deep learning and cancer pathology. As the country’s first to obtain Korea’s MFDS (Ministry of Food and Drug Safety) approval of an AI-based cancer diagnostic support solution, Deep Bio’s vision is to radically improve efficiency and accuracy of pathologic cancer diagnosis and prognosis, by equipping pathologists with deep learning-based IVD SaMDs (In Vitro Diagnostics Software as a Medical Device), for optimal cancer treatment decisions. Deep Bio is also actively engaged in the research space and maintains ongoing collaborations with top US medical centers. To learn more, visit

    DeepDx® Prostate is a clinically-validated AI for prostate core needle biopsy tissue image analysis. Whole-slide images (WSIs) of H&E-stained biopsy tissue specimens are analyzed for prostate cancer, Gleason scores, and grade groups. Extensively tested at US CLIA labs (700k cores between 2019 and 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity and variability.” To learn more, visit